Gilead Sciences Operating Income 2010-2022 | GILD
Gilead Sciences annual/quarterly operating income history and growth rate from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- Gilead Sciences operating income for the quarter ending March 31, 2022 was $0.197B, a 93.18% decline year-over-year.
- Gilead Sciences operating income for the twelve months ending March 31, 2022 was $7.225B, a 58.48% increase year-over-year.
- Gilead Sciences annual operating income for 2021 was $9.918B, a 143.63% increase from 2020.
- Gilead Sciences annual operating income for 2020 was $4.071B, a 5.04% decline from 2019.
- Gilead Sciences annual operating income for 2019 was $4.287B, a 47.72% decline from 2018.
Gilead Sciences Annual Operating Income
(Millions of US $) |
| 2021 |
$9,918 |
| 2020 |
$4,071 |
| 2019 |
$4,287 |
| 2018 |
$8,200 |
| 2017 |
$14,124 |
| 2016 |
$17,633 |
| 2015 |
$22,193 |
| 2014 |
$15,265 |
| 2013 |
$4,524 |
| 2012 |
$4,010 |
| 2011 |
$3,790 |
| 2010 |
$3,962 |
| 2009 |
$3,529 |
Gilead Sciences Quarterly Operating Income
(Millions of US $) |
| 2022-03-31 |
$197 |
| 2021-12-31 |
$940 |
| 2021-09-30 |
$3,842 |
| 2021-06-30 |
$2,246 |
| 2021-03-31 |
$2,890 |
| 2020-12-31 |
$2,651 |
| 2020-09-30 |
$2,001 |
| 2020-06-30 |
$-2,983 |
| 2020-03-31 |
$2,402 |
| 2019-12-31 |
$1,093 |
| 2019-09-30 |
$-1,473 |
| 2019-06-30 |
$2,430 |
| 2019-03-31 |
$2,237 |
| 2018-12-31 |
$1,144 |
| 2018-09-30 |
$2,623 |
| 2018-06-30 |
$2,280 |
| 2018-03-31 |
$2,153 |
| 2017-12-31 |
$2,291 |
| 2017-09-30 |
$3,812 |
| 2017-06-30 |
$4,254 |
| 2017-03-31 |
$3,767 |
| 2016-12-31 |
$4,045 |
| 2016-09-30 |
$4,399 |
| 2016-06-30 |
$4,538 |
| 2016-03-31 |
$4,651 |
| 2015-12-31 |
$5,621 |
| 2015-09-30 |
$5,585 |
| 2015-06-30 |
$5,616 |
| 2015-03-31 |
$5,371 |
| 2014-12-31 |
$4,330 |
| 2014-09-30 |
$3,480 |
| 2014-06-30 |
$4,412 |
| 2014-03-31 |
$3,043 |
| 2013-12-31 |
$1,197 |
| 2013-09-30 |
$1,148 |
| 2013-06-30 |
$1,154 |
| 2013-03-31 |
$1,025 |
| 2012-12-31 |
$1,107 |
| 2012-09-30 |
$1,044 |
| 2012-06-30 |
$1,059 |
| 2012-03-31 |
$800 |
| 2011-12-31 |
$867 |
| 2011-09-30 |
$1,004 |
| 2011-06-30 |
$1,017 |
| 2011-03-31 |
$902 |
| 2010-12-31 |
$829 |
| 2010-09-30 |
$979 |
| 2010-06-30 |
$993 |
| 2010-03-31 |
$1,161 |
| 2009-12-31 |
$1,065 |
| 2009-09-30 |
$894 |
| 2009-06-30 |
$761 |
| 2009-03-31 |
$808 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$80.075B |
$27.305B |
|
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
|
